Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $649000.0 in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $649000.0, down 44.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (down 28.59% YoY), and the FY2025 annual result was $3.6 million, down 7.18% from the prior year.
• Depreciation & Amortization (CF) eased to $649000.0 in Q1 2026 per CRBU's latest filing, from $682000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.6 million in Q3 2023 and troughed at $308000.0 in Q1 2022.
• A 5-year average of $786352.9 and a median of $682000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) jumped 250.89% in 2023, then slumped 46.39% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $506000.0 in 2022, then soared by 46.25% to $740000.0 in 2023, then surged by 60.0% to $1.2 million in 2024, then tumbled by 42.4% to $682000.0 in 2025, then decreased by 4.84% to $649000.0 in 2026.
• Business Quant data shows CRBU's Depreciation & Amortization (CF) at $649000.0 in Q1 2026, $682000.0 in Q4 2025, and $631000.0 in Q3 2025.